Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1.

Saved in:
Bibliographic Details
Title: Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1.
Authors: Soday L; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Seripracharat C; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Gray JL; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Luz AFS; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-004, Portugal., Howard RT; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Singh R; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Burden TJ; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Bernardini E; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Mateus-Pinheiro M; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-004, Portugal., Petersen J; Discovery Sciences, R&D Gothenburg, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Gunnarsson A; Discovery Sciences, R&D Gothenburg, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Gunnarsson J; Discovery Sciences, R&D Gothenburg, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Aagaard A; Discovery Sciences, R&D Gothenburg, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Sjögren T; Discovery Sciences, R&D Gothenburg, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Maslen S; The Francis Crick Institute, London NW1 1AT, U.K., Bartlett EJ; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Iles AF; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K., Smith DM; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Scott JS; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Skehel M; The Francis Crick Institute, London NW1 1AT, U.K., Davis AM; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ressurreição AS; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-004, Portugal., Moreira R; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-004, Portugal., Rodrigues CMP; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-004, Portugal., Shenoy AR; Department of Infectious Diseases, Imperial College London, Flowers Building, South Kensington Campus, London SW7 2AZ, U.K., Tate EW; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K.; The Francis Crick Institute, London NW1 1AT, U.K.
Source: ACS chemical biology [ACS Chem Biol] 2025 Jul 18; Vol. 20 (7), pp. 1527-1543. Date of Electronic Publication: 2025 Jun 20.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101282906 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1554-8937 (Electronic) Linking ISSN: 15548929 NLM ISO Abbreviation: ACS Chem Biol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1554-8937
DOI:10.1021/acschembio.5c00112